Clinical Trial

A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will assess the safety and efficacy of fixed dose combinations of ensifentrine with two different glycopyrrolate dose levels compared to placebo and to the individual components of the fixed dose combinations, each administered twice a day via standard jet nebulizer, in adult subjects with chronic obstructive pulmonary disease (COPD).
Protocol Amendment History 5 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-24
notable Enrollment increased: 480 -> 1119 participants 2026-07-24
notable Sponsor changed: Verona Pharma plc -> Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA 2026-05-10
notable Primary completion pushed: 2026-04-29 -> 2026-07-29 2026-04-10
minor Completion pushed: 2026-04-29 -> 2026-07-29 2026-04-10
Trial Details
NCT Number NCT07016412
Lead Sponsor Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 1,119 participants
Start Date 2025-07-31
Primary Completion 2026-08-17 (estimated)
Study Completion 2026-08-17 (estimated)
Updated on ClinicalTrials.gov 2026-07-23